EUVIMEDEUVIMED entdecken
Open Access

Clinical outcomes in hospitalized plasma and platelet transfusion recipients prior to and following widespread blood donor SARS‐CoV ‐2 infection and vaccination

Nareg H Roubinian, John Greene iD, Vincent X Liu, Catherine Lee, Dustin G Mark, David R Vinson, Bryan R Spencer iD, Roberta Bruhn iD, Marjorie Bravo, Mars Stone, Brian Custer iD, Steve Kleinman und 3 weitere

Transfusion · 2024

DOI: 10.1111/trf.17616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Nareg H Roubinian und 14 weiteren Autor:innen. Beteiligte Einrichtung: Kaiser Permanente Northern California Division of Research, Oakland, California, USA. Hauptthemen laut MEDLINE: Blood Donors, COVID-19, Platelet Transfusion, Blood Component Transfusion. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety of transfusion of SARS‐CoV‐2 antibodies in high plasma volume blood components to recipients without COVID‐19 is not established. We assessed whether transfusion of plasma or platelet products during periods of increasing prevalence of blood donor SARS‐CoV‐2 infection and vaccination was associated with changes in outcomes in hospitalized patients without COVID‐19.

Methods

We conducted a retrospective cohort study of hospitalized adults who received plasma or platelet transfusions at 21 hospitals during pre‐COVID‐19 (3/1/2018–2/29/2020), COVID‐19 pre‐vaccine (3/1/2020–2/28/2021), and COVID‐19 post‐vaccine (3/1/2021–8/31/2022) study periods. We used multivariable logistic regression with generalized estimating equations to adjust for demographics and comorbidities to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Results

Among 21,750 hospitalizations of 18,584 transfusion recipients without COVID‐19, there were 697 post‐transfusion thrombotic events, and oxygen requirements were increased in 1751 hospitalizations. Intensive care unit length of stay ( n = 11,683) was 3 days (interquartile range 1–5), hospital mortality occurred in 3223 (14.8%), and 30‐day rehospitalization in 4144 (23.7%). Comparing the pre‐COVID, pre‐vaccine and post‐vaccine study periods, there were no trends in thromboses (OR 0.9 [95% CI 0.8, 1.1]; p = .22) or oxygen requirements (OR 1.0 [95% CI 0.9, 1.1]; p = .41). In parallel, there were no trends across study periods for ICU length of stay ( p = .83), adjusted hospital mortality (OR 1.0 [95% CI 0.9–1.0]; p = .36), or 30‐day rehospitalization ( p = .29).

Discussion

Transfusion of plasma and platelet blood components collected during the pre‐vaccine and post‐vaccine periods of the COVID‐19 pandemic was not associated with increased adverse outcomes in transfusion recipients without COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood DonorsCOVID-19Platelet TransfusionBlood Component TransfusionAdultHumansOxygenRetrospective StudiesVaccinationCOVID-19 VaccinesPlasmaHospitalization

Substanzen

OxygenCOVID-19 Vaccines

Autor:innen und Institutionen

  • Kaiser Permanente Northern California Division of Research, Oakland, California, USA.
  • Vitalant Research Institute, San Francisco, California, USA.
  • Department of Laboratory Medicine, UCSF, San Francisco, California, USA.
  • American Red Cross, Scientific Affairs, Dedham, Massachusetts, USA.
  • Vitalant, Scottsdale, Arizona, USA.
  • University of British Columbia, Vancouver, British Columbia, Canada.

ORCID-Profile: John Greene, Bryan R Spencer, Roberta Bruhn, Brian Custer, Philip J Norris

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Roubinian, N. H., Greene, J., Liu, V. X., Lee, C., Mark, D. G., Vinson, D. R., Spencer, B. R., Bruhn, R., Bravo, M., Stone, M., Custer, B., Kleinman, S., Busch, M. P., Norris, P. J., & NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-P (REDS-IV) (2024). Clinical outcomes in hospitalized plasma and platelet transfusion recipients prior to and following widespread blood donor SARS‐CoV ‐2 infection and vaccination. Transfusion. https://doi.org/10.1111/trf.17616

Vancouver

Roubinian NH, Greene J, Liu VX, Lee C, Mark DG, Vinson DR, et al. Clinical outcomes in hospitalized plasma and platelet transfusion recipients prior to and following widespread blood donor SARS‐CoV ‐2 infection and vaccination. Transfusion. 2024. doi:10.1111/trf.17616

BibTeX
@article{Roubinian2024,
  author = {Roubinian, Nareg H and Greene, John and Liu, Vincent X and Lee, Catherine and Mark, Dustin G and Vinson, David R and Spencer, Bryan R and Bruhn, Roberta and Bravo, Marjorie and Stone, Mars and Custer, Brian and Kleinman, Steve and Busch, Michael P and Norris, Philip J and NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-P (REDS-IV), NHLBI Recipient Epidemiology and Donor Evaluation Study-IV-P (REDS-IV)},
  title = {Clinical outcomes in hospitalized plasma and platelet transfusion recipients prior to and following widespread blood donor SARS‐CoV ‐2 infection and vaccination},
  journal = {Transfusion},
  year = {2024},
  doi = {10.1111/trf.17616}
}
Kostenlos starten →